

# Blood Transcriptomic Biomarkers of Alzheimer's Disease Patients Treated with EHT 0202

Laurent Désiré<sup>a,\*</sup>, Elodie Blondiaux<sup>b</sup>, Jennifer Carrière<sup>a</sup>, Raphael Haddad<sup>a</sup>, Olivier Sol<sup>a</sup>, Pascale Fehlbaum-Beurdeley<sup>a</sup>, Rich Einstein<sup>a</sup>, Weiyin Zhou<sup>a</sup> and Matthew P. Pando<sup>a</sup>

<sup>a</sup>*Exonhit SA, Paris, France*

<sup>b</sup>*Effi-Stat, Paris, France*

Handling Associate Editor: Barbara Borroni

Accepted 13 November 2012

Supplementary Table 1  
Primary demographic and clinical variables of the transcript profiled patient population


Variable	Placebo responder	Placebo decliner	EHT 0202 40 mg bid responder	EHT 0202 40 mg bid decliner	EHT 0202 80 mg bid responder	EHT 0202 80 mg bid decliner
Size (n)	10	10	10	10	10	10
Gender (% male)	50	40	50	60	20	50
ApoE genotype (% ε4 positive)	50	44 (n=9) <sup>1</sup>	50 (n=8) <sup>1</sup>	22 (n=9) <sup>1</sup>	77 (n=9) <sup>1</sup>	33 (n=9) <sup>1</sup>
Age (years)	77.4 ± 6.93	80.9 ± 4.74	78.6 ± 9.25	81.2 ± 5.95	80.6 ± 4.67	77.4 ± 7.15
MMSE <sup>2</sup>	0 ± 2.21	-2.1 ± 3.44	0.6 ± 1.77	-1.7 ± 3.59	-1.1 ± 4.0	-1.4 ± 2.54
ADAS-Cog <sup>2</sup>	-3.2 ± 1.7	6.4 ± 3.08	-2.1 ± 1.27	6.0 ± 3.36	-3.53 ± 0.80	7.3 ± 3.82
Body mass index	23.2 ± 2.78	23.4 ± 2.54	25.5 ± 6.43	25.4 ± 3.32	25.3 ± 4.11	23.6 ± 3.09
Systolic blood pressure	138.9 ± 9.46	128.0 ± 12.29	131.1 ± 13.11	134.3 ± 14.27	132.8 ± 13.1	141.1 ± 14.86
Stable AChEI treatment length (months)	15.3 ± 12.24	13.6 ± 13.24	10.8 ± 8.18	19.2 ± 20.01	22.0 ± 17.96	22.3 ± 16.15
AChEI treatment <sup>3</sup>	galantamine 40% (n=4) donepezil 60% (n=6)	galantamine 50% (n=5) donepezil 50% (n=5)				

Data are baseline values except otherwise noted. <sup>1</sup>Sample size of the subgroup population which was effectively genotyped. <sup>2</sup>Change from baseline (Visit 2, the day before study treatment initiation) to endpoint (Visit 5, study treatment termination). <sup>3</sup> Percentage and number of patients treated in each group. AChEI, acetylcholinesterase inhibitor; ADAS-Cog, Alzheimer's Disease Assessment Scale - cognitive subscale; ApoE, Apolipoprotein E; MMSE, Mini-Mental State Examination.

Supplementary Table 2 (Excel file), available here:  
<http://www.j-alz.com/issues/34/vol34-2.html#supplementarydata0801>

Supplementary Table 3 (Excel file), available here:  
<http://www.j-alz.com/issues/34/vol34-2.html#supplementarydata0802>

\*Correspondence to: Laurent Désiré, Exonhit SA, 63–65 boulevard Masséna, 75013 Paris, France. Tel.: +33 1 53 94 77 09; Fax: +33 1 53 94 77 07; E-mail: laurent.desire@exonhit.com.



Supplementary Figure 1. Functional classification of the genes from the pre-treatment at visit 2 (V2) and post-treatment at visit 5 (V5) EHT 0202 signatures. A significant number of genes from both signatures are involved in, or associated with the main biological and the pathophysiological processes in Alzheimer's disease. Gene numbers are given for each category. Genes in red exhibit upregulated probe sets in improving patients while genes in green exhibit down-regulated probe sets in improving patients. Post-treatment, the signature genes that discriminate responding from declining subjects are less numerous in each category except vascular disorder (no change), and gene expression, carbohydrate and lipid metabolism functions (all three highly enriched in the post-treatment signature). Mitochondrial function, oxidative stress and calcium signaling are shown for information but were not significantly represented in the two signatures. Threshold for significance:  $p < 0.05$  by the right-tailed Fisher's exact test.